Marco Ruella, ASH 2021: Resistance Mechanisms to CAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (PART TWO)
Dr Marco Ruella (University of Pennsylvania, Philadelphia, PA, USA) discusses his presentation at the 63rd ASH Annual Meeting & Exposition on resistance mechanisms to CAR-T cells in patients with B-cell acute lymphoblastic leukemia. (PART TWO)
1. Could you give us an overview of the mechanisms of chimeric antigen receptor (CAR) T-cell resistance? 00:15-05:28
2. What strategies are being explored to prevent and treat CAR-T cell resistance? 05:28-09:16
Speaker Disclosure: Marco Ruella discloses research support from Abclon, nanoString and Beckman-Coulter; advisory board membership from Abclon, Bayer, CART Tech, UPenn (partly licensed to Novartis), Tmunity, viTToria biotherapeutics, GSK and Sana; consultancy from nanoString and BMS and is the scientific founder of viTToria biotherapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 63rd ASH Annual Meeting & Exposition
Share this Video
Related Videos In Immuno-oncology
Tumour-selective targeted delivery of antibody-cytokine fusion proteins: Jamie Spangler, AACR 2023
Antibody-cytokine fusion proteins are a promising immunotherapy that could overcome off-target immune cell activation and the short serum half-life associated with low-dose interleukin-2 treatment. We were delighted to talk with Dr. Jamie Spangler (Johns Hopkins University, Baltimore, MD, USA) around the rationale for fusing cytokines to anti-cytokine antibodies in targeted therapy, the improved therapeutic efficacy […]
DNA damage as a target and predictor of treatment response in immunotherapy: Sandra Demaria, AACR 2023 (Part 2)
A defective DNA damage response in cancer cells can lead to genomic instability and impact the immunogenicity of tumours, improving the efficacy of immunotherapy treatment approaches. It was a pleasure to talk with Professor Sandra Demaria (Weill Cornell Medicine, New York, NY, USA) to discuss how radiation-induced DNA damage is targeted in treatment strategies with immunotherapy, […]
Radiation-induced DNA damage response and tumour immunogenicity: Sandra Demaria, AACR 2023 (Part 1)
A defective DNA damage response in cancer cells can lead to genomic instability and impact the immunogenicity of tumours, improving the efficacy of immunotherapy treatment approaches. We were delighted to talk with Professor Sandra Demaria (Weill Cornell Medicine, New York, NY, USA) around the radiation-induced DNA damage response, its association with cancer and how this […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!